Company intelligence / Profile preview

AddGab

Geneva, Geneva, Switzerlandflickr.com ↗

Ownership: Private
Development stage: Other

Overview

Addex Therapeutics is a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug discovery for neurological disorders. Its lead partnered program, a GABAB positive allosteric modulator for substance use disorder, has advanced through IND-enabling studies with Indivior. Another key asset, ADX71149, is in Phase 2 trials for epilepsy with Janssen Pharmaceuticals. The company also has preclinical programs targeting chronic cough, pain, CMT1A, stress-related and neurocognitive disorders

Therapeutic areas: PulmonologyPsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Indivior PLC — collaboration on GABAB PAM for substance use disorderJanssen Pharmaceuticals — partnership on ADX71149 epilepsy program

Beyond the preview

Go deeper on AddGab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AddGab.

Explore the full profile